SECOND AMENDMENT TO LICENSE AGREEMENT NO. 2000-03-0591
QuickLinks -- Click here to rapidly navigate through this document
SECOND AMENDMENT
TO
LICENSE AGREEMENT NO. 0000-00-0000
This Second Amendment is made and is effective this 15th day of May 2001 (the Effective Date) by and between The Regents of the University of California ("The Regents"), a California corporation having its statewide administrative offices at 0000 Xxxxxxxx Xxxxxx, 00xx Xxxxx, Xxxxxxx, Xxxxxxxxxx 00000-0000, acting through the offices of The University of California, Los Angeles located at 00000 Xxxxxxxx Xxxx., Xxxxx 0000, Xxx Xxxxxxx, Xxxxxxxxxx 00000-0000, and Prometheus Laboratories, Inc. ("Prometheus"), a California corporation having a principal place of business at 0000 Xxxxxxx Xxxxxx Xxxxxxxxx, Xxx Xxxxx, Xxxxxxxxxx 00000 and amends the License Agreement dated December 1, 1999 (the "Agreement").
Whereas Exhibit A defining Regents and Cedars-Sinai Medical Center Joint Inventions Patent Rights is amended to include an invention known as "Methods of Diagnosing and Treating Crohn's Disease Using Pseudomonas Antigens" (UC Case No. 2001-114-1) developed by Xxxxxxxx Xxxxx, Xx Xxx and Xxxxxxxxxxx Xxxxxx. A Provisional application based on this technology was filed in the U.S. Patent and Trademark Office on October 13, 2000, Serial No. 60/240,347.
Upon execution of this Amendment Prometheus will pay The Regents $5,000 as consideration for this Amendment.
All other terms and conditions remain the same.
| Prometheus Laboratories, Inc. | |||
By: |
/s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx, Chairman of the Board |
July 12, 2001 Date |
|
The Regents of the University of California |
|||
By: |
/s/ Xxxxx Xxxxxxx Xxxxx Xxxxxxx Assistant Director Office of Intellectual Property Admin. |
July 19, 2001 Date |
|
